Biotech Values

[growacet]

Resverlogix, Canadian Small Cap biotech in Phase 3.....

News today about a peer reviewed article in the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

https://ca.finance.yahoo.com/news/resverlogix-announces-publication-apabetalone-high-123000424.html

USD market cap is over $650 million USD after today's trading, ~200 million shares outstanding, but most insider held....trading is extremely light. Currently no US listing, its a Calgary based company that trades on Canada's big board TSX. With no listing in the states it currently trades OTC in the US with the symbol RVXCF.

The company has disclosed working with Paris based Rothschild & Co on efforts to secure a Nasdaq listing, but not expecting anything on that front until top-line results from their Phase 3 trial BETonMACE are released.

Company is poorly financed with an outstanding loan coming due in August...the drug is Apabetalone and it has shown potential in a number of indications including Diabetes, Kidney Disease and Alzheimers...the current trial is for Diabetics at high risk of a Major Adverse Cardiac Event as well as having low HDL. There are subsets of patients suffering from Kidney Disease as well as Cognitive impairment....

Risky as....but if they hit their end points imo this is heading to a MCap in the billions, $5 billion+ USD would not surprise me....

Questions and "Bashing" welcome...it is high risk.